BLINCYTO® (blinatumomab) is a prescription medication used to treat a certain type of acute lymphoblastic leukemia (ALL) in adults and children. ...read more
BLINCYTO® is given by a continuous intravenous (IV) infusion. This means the medicine goes into your body through a vein. This happens for a 4-week period.1,2
The dosing of BLINCYTO® occurs in cycles. Here’s how a cycle works:1
One cycle is 4 weeks of infusion followed by 2 weeks without infusion.1
In the study of BLINCYTO®, most people were given 1 or 2 cycles.1 Your doctor will decide how long you will need to stay on treatment.
BLINCYTO® treatment starts in the hospital to make sure that it is safe for you and to prevent any reactions that may occur.1
Afterward, your doctor will decide if you can get the rest of your treatment at home, if that is right for you. Or your doctor may refer you to an outpatient clinic or an infusion center to manage your treatment.
*The 7-day infusion is not recommended for patients weighing less than 22 kg.
If it feels overwhelming to receive BLINCYTO® away from the hospital, you have support options. Your health care team may be able to help make sure you are prepared. Here are some notes about receiving BLINCYTO® at home:
Talk to your health care provider about whether your IV bag will be changed at an outpatient center or by your home health care provider
Call your doctor if you experience any problems or side effects
Do not change the settings on your pump, even if the alarm sounds. Any setting changes may cause a dose error
If you are having any problems with your pump, or pump alarm sounds, contact your health care provider immediately
Keep BLINCYTO® and all medicines out of reach of other children in the household
What is the most important information I should know about BLINCYTO®?
Who should not receive BLINCYTO®?
What should I avoid while receiving BLINCYTO®?
Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:
BLINCYTO® (blinatumomab) is a prescription medication used to treat a certain type of acute lymphoblastic leukemia (ALL) in adults and children. ALL is a cancer of the blood and bone marrow in which a particular kind of white blood cell is replicating out of control.
What is the most important information I should know about BLINCYTO®?
References: 1. BLINCYTO® (blinatumomab) prescribing information, Amgen. 2. National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/ cancer-terms. Accessed October 9, 2019. 3. BLINCYTO® (blinatumomab) medication guide, Amgen.